Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib.
MDR-ABC transporters
chronic myeloid leukemia
drug resistance
molecular response
nilotinib
polymorphisms
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
02
2021
accepted:
21
04
2021
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
1
6
2021
Statut:
epublish
Résumé
Tyrosine kinase inhibitors (TKIs) have radically changed the outcome of chronic myeloid leukemia (CML) patients in the last 20 years. Moreover, the advent of second generation TKIs, namely nilotinib and dasatinib, have largely increased the number of CML patients achieving deep and sustained molecular responses. However, the possible mechanisms capable of influencing the maintenance of the long-term molecular response are not yet fully known and understood. In this light, polymorphisms in MDR-ABC transporters may influence the efficacy and safety of TKIs. In this study, we examined seven single nucleotide polymorphisms (SNPs) in four ABC transporter genes: ABCC1 rs212090 (5463T>A), ABCC2 rs3740066 (3972C>T), ABCC2 rs4148386 G>A, ABCC2 rs1885301 (1549G>A), ABCG2 rs2231137 (34G>A), ABCG2 rs2231142 G>C, ABCB1 rs1045642 (3435C>T), to determine their effect on the achievement and/or loss of molecular response in 90 CML patients treated with nilotinib. We found that
Identifiants
pubmed: 34055641
doi: 10.3389/fonc.2021.672287
pmc: PMC8155509
doi:
Types de publication
Journal Article
Langues
eng
Pagination
672287Informations de copyright
Copyright © 2021 Loscocco, Visani, Ruzzo, Bagaloni, Fuligni, Galimberti, Di Paolo, Stagno, Pregno, Annunziata, Gozzini, Barulli, Gabucci, Magnani and Isidori.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leuk Lymphoma. 2020 Jan;61(1):98-107
pubmed: 31409168
Cancer Chemother Pharmacol. 2017 Oct;80(4):829-839
pubmed: 28836054
Oncotarget. 2018 Feb 3;9(17):13423-13437
pubmed: 29568367
Leuk Res. 2016 Dec;51:3-10
pubmed: 27770655
Clin Cancer Res. 2003 Feb;9(2):625-32
pubmed: 12576428
J Clin Pharm Ther. 2014 Dec;39(6):685-90
pubmed: 25060527
Leukemia. 2007 Jun;21(6):1267-75
pubmed: 17519960
Molecules. 2014 Mar 19;19(3):3356-75
pubmed: 24651611
Blood. 2006 Jul 1;108(1):28-37
pubmed: 16522812
Curr Hematol Malig Rep. 2019 Dec;14(6):507-514
pubmed: 31701369
Leuk Lymphoma. 2013 Mar;54(3):569-78
pubmed: 22845311
Leukemia. 2020 Apr;34(4):966-984
pubmed: 32127639
Front Oncol. 2019 Aug 06;9:665
pubmed: 31448223
Genomics Proteomics Bioinformatics. 2016 Oct;14(5):298-313
pubmed: 27729266
J Pers Med. 2018 Dec 05;8(4):
pubmed: 30563187
Lancet Haematol. 2019 Jul;6(7):e375-e383
pubmed: 31201085
Front Oncol. 2019 Jul 03;9:603
pubmed: 31334123
Clin Cancer Res. 2009 Dec 15;15(24):7519-7527
pubmed: 20008852
Sci Rep. 2016 Jul 12;6:29559
pubmed: 27405085
Mol Diagn Ther. 2017 Dec;21(6):621-631
pubmed: 28698977
Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):266-271
pubmed: 29510895
Leukemia. 2017 Dec;31(12):2844-2847
pubmed: 28819281
Cancer Control. 2009 Apr;16(2):122-31
pubmed: 19337198
Br J Pharmacol. 2009 Oct;158(4):1153-64
pubmed: 19785662
PLoS One. 2018 Jan 31;13(1):e0192180
pubmed: 29385210
Mediterr J Hematol Infect Dis. 2015 Feb 15;7(1):e2015014
pubmed: 25745541
Blood. 2008 Sep 1;112(5):2024-7
pubmed: 18524988
Pharmacol Res. 2013 Jan;67(1):79-83
pubmed: 23103446
Pharmacogenomics. 2018 Apr;19(5):475-393
pubmed: 29569526
Blood. 2002 Jul 1;100(1):367-8; author reply 368-9
pubmed: 12096719
Front Oncol. 2019 Sep 24;9:939
pubmed: 31612105
Leukemia. 2017 Jan;31(1):75-82
pubmed: 27416909